Presentation is loading. Please wait.

Presentation is loading. Please wait.

Comparison of the efficacy and safety of entecavir and tenofovir in nucleos(t)ide analogue-naive chronic hepatitis B patients with high viraemia: a retrospective.

Similar presentations


Presentation on theme: "Comparison of the efficacy and safety of entecavir and tenofovir in nucleos(t)ide analogue-naive chronic hepatitis B patients with high viraemia: a retrospective."— Presentation transcript:

1 Comparison of the efficacy and safety of entecavir and tenofovir in nucleos(t)ide analogue-naive chronic hepatitis B patients with high viraemia: a retrospective cohort study  I.-T. Wu, T.-H. Hu, C.-H. Hung, S.-N. Lu, J.-H. Wang, C.-M. Lee, C.-H. Chen  Clinical Microbiology and Infection  Volume 23, Issue 7, Pages (July 2017) DOI: /j.cmi Copyright © 2017 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions

2 Fig. 1 Comparison of virological response between entecavir and tenofovir among hepatitis B e antigen (HBeAg) -positive (a) and HBeAg-negative (b) patients in propensity-score matching group. Clinical Microbiology and Infection  , DOI: ( /j.cmi ) Copyright © 2017 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions

3 Fig. 2 Comparison of virological response between entecavir and tenofovir among all patients (a) and hepatitis B e antigen (HBeAg) -positive patients (b) with baseline hepatitis B virus DNA >8 log10 IU/mL. Clinical Microbiology and Infection  , DOI: ( /j.cmi ) Copyright © 2017 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions

4 Fig. 3 Comparison of hepatocellular carcinoma (HCC) between entecavir and tenofovir among all patients (a) and patients with cirrhosis (b). Clinical Microbiology and Infection  , DOI: ( /j.cmi ) Copyright © 2017 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions

5 Fig. S1.Comparison of hepatitis B e antigen (HBeAg) loss (a) and seroconversion (b) between entecavir and tenofovir among all HBeAg-positive patients. Clinical Microbiology and Infection  , DOI: ( /j.cmi ) Copyright © 2017 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions

6 Fig. S2.(a) Comparison of cumulative incidence of drug-related acute kidney injury (AKI) between entecavir and tenofovir. (b) Serial mean estimated glomerular filtration rate (eGFR) values during entecavir and tenofovir treatment. Clinical Microbiology and Infection  , DOI: ( /j.cmi ) Copyright © 2017 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions


Download ppt "Comparison of the efficacy and safety of entecavir and tenofovir in nucleos(t)ide analogue-naive chronic hepatitis B patients with high viraemia: a retrospective."

Similar presentations


Ads by Google